PMB Technology Berhad Reports Third Quarter 2024 Earnings
November 30, 2024 - 06:30
PMB Technology Berhad has announced its financial results for the third quarter of 2024, revealing an earnings per share (EPS) of RM0.005. This marks a notable increase from the EPS of RM0.001 reported during the same period in 2023. The company's revenue for the quarter stood at RM209.8 million, reflecting a decline of 29% compared to the previous year.
The decrease in revenue has raised concerns among analysts, as it suggests potential challenges in the market environment. Despite the drop in revenue, the improvement in EPS indicates that the company has managed to enhance its operational efficiency or reduce costs effectively.
Investors will be keenly observing how PMB Technology navigates the current economic landscape and whether it can sustain its profitability in the coming quarters. The management is expected to provide insights into strategies aimed at reversing the revenue decline and fostering growth in future earnings.
MORE NEWS
August 17, 2025 - 09:27
A Critical Look at Marvell Technology's FutureRecent analyses have surfaced a bearish perspective on Marvell Technology, Inc., highlighting potential challenges the company may face in the near future. As of August 8th, Marvell`s shares were...
August 16, 2025 - 17:26
Tuniu Achieves Significant Growth in Second Quarter of 2025Tuniu has reported impressive results for the second quarter of 2025, showcasing a robust 15.3% increase in revenue compared to the previous year. This growth marks a significant milestone for the...
August 16, 2025 - 03:39
Ethical Concerns Fueling a New Wave of AI VeganismIn recent years, a growing movement known as `AI veganism` has emerged, driven by ethical considerations surrounding the treatment of content creators and the implications of artificial...
August 15, 2025 - 00:29
Innovative Breast Cancer Treatment Technology Debuts at Morton Plant HospitalBayCare`s Morton Plant Hospital in Clearwater has introduced groundbreaking technology aimed at enhancing the treatment of breast cancer. This state-of-the-art system is notable for being the first...